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ABSTRACT
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis
of skin and numerous internal organs and a severe fibroproliferative vasculopathy resulting
frequently in severe disability and high mortality. Although the etiology of SSc is unknown and
the detailed mechanisms responsible for the fibrotic process have not been fully elucidated one
important observation from a large U.S. population study was the demonstration of a late onset
of SSc with a peak incidence between 45 and 54 years of age in African-American females and
between 65 and 74 years of age in white females. Although it is not appropriate to consider SSc
as a disease of aging, the possibility that senescence changes in the cellular elements responsible
for its development may play a role has not been thoroughly examined. The process of cellular
senescence is extremely complex and the mechanisms, molecular events, and signaling pathways
involved have not been fully elucidated, however, there is strong evidence to support the concept
that oxidative stress caused by the excessive generation of reactive oxygen species may be one
important mechanism involved. On the other hand, numerous studies have implicated oxidative
stress in SSc pathogenesis, thus, suggesting a plausible mechanism in which excessive oxidative
stress induces cellular senescence and that the molecular events associated with this complex
process play an important role in the fibrotic and fibroproliferative vasculopathy characteristic
of SSc. Here, recent studies examining the role of cellular senescence and of oxidative stress in
SSc pathogenesis will be reviewed.
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INTRODUCTION
Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology characterized
by progressive fibrosis of skin and numerous internal organs and a severe fibroproliferative
vasculopathy resulting frequently in functional disability and high mortality [1-3]. The
pathogenesis of SSc is complex and despite numerous studies that have examined its intricate
picture, the exact mechanisms involved in the severe cutaneous and systemic fibrotic process
have not been fully elucidated [4-7]. One important demographic feature identified in a large SSc
population is that SSc disease onset and its peak incidence occur between the ages of 45 and 54
years for African American women and between the ages of 65 and 74 years for white women
[8]. The reasons for the late onset and higher frequency of SSc in individuals older than 45 years
of age are not known and have not been examined in detail. Although it is not appropriate to
consider SSc as a disease of aging, the possible role of cellular senescence in SSc pathogenesis
should be considered as an important factor. Among the reactions or pathways that may be
involved in this process there is strong evidence that oxidative stress mediated by an excessive
generation of reactive oxygen species (ROS) plays a crucial role. We will review here recent
experimental evidence supporting the participation of cellular senescence and oxidative stress in
SSc pathogenesis emphasizing the potential role of oxidative stress in the fibrotic process that is
the hallmark of SSc. We will also discuss recent evidence indicating that the NADPH oxidase
NOX4 may be one of the most important mediators of ROS generation in SSc, and the
potentially beneficial effects of inhibition of NOX4 activity as a cogent therapeutic approach for
SSc-associated tissue fibrosis and fibroproliferative vasculopathy.
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CELLULAR SENESCENCE AND SSc PATHOGENESIS.
Cellular Senescence and Senescence Associated Secretory Phenotype.
Cellular senescence, a process first identified by Hayflick and Moorehead in their pioneering
studies on human diploid fibroblasts cultured in vitro [9,10], is characterized by the permanent
arrest of cell division associated with a variety of phenotypic changes including cellular
enlargement, flattening, and vacuolization, as well as, numerous functional alterations [Reviewed
in 11-16]. The most prominent of these alterations are the expression of novel specific gene
products such as the senescence-associated β-galactosidase isoform (SA-β gal), and the
acquisition of a unique complement of secreted molecules which includes inflammatory
cytokines and chemokines, growth factors, and various proteases and other pro-inflammatory
molecules collectively known as the senescence-associated secretory phenotype or SASP [17**21]. The most important pro-inflammatory and pro-fibrotic SASP components are listed in Table
1. Although it was initially considered that cellular senescence may be solely a protective
mechanism to prevent the uncontrolled cellular proliferative activity of malignant cells, extensive
studies have demonstrated that it may participate in numerous physiological processes including
embryonic development [22**,23**], as well as in pathologic conditions associated with aging
[11-13, 24,25].
The mechanisms responsible for the irreversible arrest in cellular proliferative capacity are
highly complex and although they have been studied extensively, they have not been fully
elucidated. However, it has been shown that a variety of stimuli and numerous signaling
pathways may be involved [11-13, 16,18]. The most important triggers of cellular senescence are
the activation of the DNA-damage response (DDR) initiated by the occurrence of structural
changes in DNA and complex molecular events involving oncogene effects, abnormalities in cell
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cycle kinases, including various cyclin-dependent kinases, and telomere shortening or
dysfunction [11-13, 26-28]. Of relevance to the topic of this review are the extensive
observations demonstrating that two important mechanisms involved in cellular senescence are
reactive oxygen species (ROS)-induced oxidative stress [29-34] and persistent stimulation by
type I interferons [35-37].
Cellular Senescence and SSc.
There has been strong interest in the role of cellular senescence in malignancies and disorders of
aging, however, there is very little information about its possible contribution to SSc
pathogenesis. Among the few investigations that have explored the possible connection between
senescence, aging, and SSc, a recent study conducted an evaluation of normal fibroblasts
obtained from donors of various ages (up to 33 years of age) and of several dermal fibroblast cell
strains obtained from patients with SSc employing a proteomic approach [38**]. The study
identified numerous age-dependent differences including the accumulation of SA-βgal and
showed that SSc fibroblasts displayed evidence indicative of cellular senescence and decreased
autophagy. Another study [39] examined bone marrow derived mesenchymal stem cells from
SSc patients and demonstrated that these cells displayed markers of early senescence and had an
impairment in their ability to differentiate into endothelial cells suggesting that these alterations
may be important for the pathogenesis of the vascular involvement in SSc.
Numerous studies have examined alterations in telomere length as playing a role in the
development of various autoimmune diseases including rheumatoid arthritis, systemic lupus
erythematosus, SSc, and Sjögren syndrome, however, the available evidence is not conclusive
and may be even contradictory in some studies [40,41]. There are very few studies of telomere
length in SSc [42-44]. Although an early study described that telomere length was significantly
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shortened in SSc patients and suggested that this observation may be either reflective of a genetic
predisposition to chromosomal instability or the result of exposure to a noxious environmental
agent [42], a more recent study described contradictory results demonstrating that telomere
length was longer in peripheral blood mononuclear cells from SSc patients [44]. Therefore, the
original description of shortened telomeres in cells from SSc patients requires further
experimental validation. In this respect, a study of telomerase activity in peripheral blood
mononuclear cells from patients with various autoimmune diseases demonstrated that in contrast
with cells from patients with rheumatoid arthritis and systemic lupus erythematosus that
displayed elevated activity of the enzyme, cells from SSc patients had remarkably low levels of
telomerase activity [45]. However, the significance of this observation to SSc pathogenesis has
not been elucidated.
Although not directly related to SSc pathogenesis, several studies of another fibrotic disease that
displays a clear pattern of increased occurrence in older individuals; namely idiopathic
pulmonary fibrosis (IPF), have provided evidence to support the notion that cellular senescence
may play an important role in its pathogenesis [46-48]. Indeed, recent studies showed an
unexpectedly high frequency of telomerase mutations and telomere shortening in a large
population of patients affected with the familial form of IPF [49,50].
Caveolin-1 and PTEN in cellular senescence.
Strong experimental evidence has demonstrated that caveolin-1 (cav-1), the protein responsible
for the remarkable functional properties of caveolae, is decreased in affected cells and tissues
from SSc or IPF patients [51-54]. Numerous recent studies have shown that cav-1 plays and
important role in the pathophysiology of tissue fibrosis [51,52,55**] most likely, owing to its
ability to induce internalization of activated TGF-β receptors into cav-1 lipid rafts leading to
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their rapid proteasomal degradation [52,55**]. Although an earlier study indicated that
expression of cav-1 induced premature cellular senescence in primary cultures of murine
fibroblasts [56], and a more recent investigation demonstrated that cav-1 deficiency protects
from bleomycin-induced pulmonary fibrosis in mice [57], recent evidence indicates that cav-1
exerts antifibrotic effects by modulating the activity of the phosphatase and tensin homolog
(PTEN). PTEN is a tumor suppressor protein that has been implicated in cellular senescence. A
recent study found that PTEN was markedly decreased in lung fibroblasts from IPF patients as
well as in lungs from mice with bleomycin-induced pulmonary fibrosis and that this reduction
was mediated by decreased cav-1 [58]. In light of previous studies demonstrating that a reduction
of PTEN exerted potent pro-fibrotic effects in vitro and in vivo [59], the newly uncovered
interaction between cav-1, PTEN and cellular senescence represents a novel pro-fibrotic
mechanism that may be of relevance to SSc pathogenesis.
ROS and OXIDATIVE STRESS IN SSc PATHOGENESIS.
Evidence of oxidative stress in SSc.
In 1993, Murrell proposed a unifying hypothesis to explain the pathogenesis of the cutaneous
fibrotic process in a variety of systemic fibrotic disorders including SSc suggesting a crucial role
for oxygen free radical induced oxidative stress [60]. Following this report numerous studies
have provided experimental support for this hypothesis and explored the mechanisms involved
[Reviewed in 61- 63]. It has been shown that oxidative stress in SSc is the result of an imbalance
between the production of oxidative stress producing systems and their antagonist antioxidant
mechanisms. Increased generation or overproduction of ROS appears to be the main mechanism
whereas ROS inactivation plays a less important role. Although one recent study demonstrated
increased levels of antioxidants in serum of about 25% of SSc patients as measured by a total
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antioxidant power assay [64**], numerous other studies have shown increased ROS production
by various cells in SSc, as well as elevated levels in plasma from SSc patients [65*-69]
providing strong evidence for the important contribution of oxidative stress in SSc pathogenesis.
A recent study compared the total oxidant status (TOS), total antioxidant status (TAS) and an
oxidative stress index (OSI) between SSc patients and healthy volunteers. The results
demonstrated that TOS and OSI levels were significantly higher in SSc patients than in controls,
whereas there were no significant differences in TAS between the two groups [65**]. These
results indicated a remarkable imbalance between the profoundly increased oxidative stress
levels and the relatively insufficient antioxidant status in SSc. In agreement with these
observations elevated levels of various oxidative stress-related products have been detected in
various biological fluids from SSc patients including increased urinary 8-oxodG levels [70], and
increased levels of isoprostanes in SSc serum [71,72], in the urine [73,74] or in exhaled breath
[75]. Isoprostanes such as F2-isoprostanes are markers of lipid peroxidation [76], produced in
vivo in humans by free radical-catalyzed peroxidation of arachidonic acid. Other markers of
oxidative stress in SSc include increased serum levels of N(epsilon)-(hexanoyl)lysine [77] and
elevated serum levels of heat shock protein 70 [78]. The functional relevance of the elevated
oxidative stress components in the circulation of SSc patients was evidenced in one recent study
showing that sera from patients with SSc pulmonary hypertension caused oxidative stress
induced activation of collagen synthesis in human pulmonary smooth muscle cells [79].
Role of ROS in SSc fibrosis and fibroproliferative vasculopathy.
ROS are a group of oxygen-derived molecules characterized by high chemical reactivity. It has
been recently recognized that under physiological conditions ROS play important functions in
intracellular signaling by activating redox-sensitive pathways including the cellular responses to
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growth factor stimulation and the establishment of inflammatory responses [Reviewed in 80-82].
However, in pathological states, higher ROS levels can induce oxidative stress causing damage
to proteins, lipids, and DNA, as well as inducing cellular senescence as discussed above.
Following Murrell’s provocative hypothesis linking SSc pathogenesis to the deleterious effects
of ROS [60] numerous studies have implicated excessive oxidative stress and the generation of
deleterious ROS in the pathogenesis of SSc [Reviewed in 61-63]. The studies of Sambo et al.
[69] provided elegant experimental evidence that SSc dermal fibroblasts produce increased
levels of ROS compared with normal cells and that the elevated ROS may be involved in the
increased expression of a profibrotic phenotype in these cells. The same group also demonstrated
that monocytes from SSc patients spontaneously release increased amounts of superoxide anion
in vitro [66]. Other studies supporting the role of ROS in the development of the fibrotic and
vasculo-proliferative lesions in SSc include the induction of high production of ROS by
endothelial cells and fibroblasts in vitro following exposure to sera from SSc patients [68] and in
pulmonary artery smooth muscle cells exposed to serum from SSc patients with pulmonary
hypertension [79], as well as the ROS mediated inhibition of the anti-Wnt protein, Wint
inhibitory factor 1 (WIF-1) leading to activation of Wnt pathway-induced tissue fibrosis (83**).
Another study described a dose dependent abrogation of the increased production and secretion
of type I collagen and fibronectin characteristic of SSc fibroblasts following in vitro exposure to
the potent antioxidant, epigallocatechin-3-gallate (EGCG). EGCG also reduced the expression of
the fibrotic marker CTGF, inhibited collagen gel contraction, and suppressed intracellular
ERK1/2 kinase signalling and NF-κB activity [84**].
Although the detailed mechanisms involved in ROS effects in induction and establishment of the
fibrotic process in SSc have not been fully elucidated there is intense ongoing research exploring
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various novel directions. Among these, one recent study described a novel mechanism by which
ROS may promote a profibrotic phenotype in SSc fibroblasts [85**]. This mechanism involves
the ROS-mediated oxidative inactivation of protein tyrosine phosphatase 1B (PTP1B) leading to
pronounced platelet derived growth factor receptor (PDGFR) activation. In this study, PTP1B
activity was significantly reduced in SSc fibroblasts, most likely as a result of increased cysteine
oxidation caused by higher levels of ROS. Confirmation of the important role of PTP1B on the
regulation of the fibrotic process was obtained from studies showing that decreased PTP1B
expression in normal fibroblasts led to increased expression of the genes encoding type I
collagen and to elevated production of the corresponding protein [85**].
NADPH OXIDASES (NOX).
The NOX family of membrane-associated enzymes catalyze the reduction of O2 to form ROS.
The crucial roles of NOX in normal cellular physiology is evidenced by the remarkable increase
in the number of NOX isoforms during eukaryotic evolution and their striking conservation
through multiple species [86,87]. Several biochemical processes and enzyme systems are capable
of producing ROS in vivo, however, the NADPH oxidases are the primary enzymes responsible
for inducible ROS formation [Reviewed in 88-90]. The role of NOX enzymes in a variety of
human disorders is currently the focus of intense investigation and numerous studies have
provided strong experimental evidence to support their participation in a variety of pathologic
conditions. Currently seven distinct NOX isoforms have been identified in humans and there are
substantial differences in their tissue distribution, however, several of them display prominent
expression in tissues and cells of substantial relevance to the pathophysiology of SSc. The three
most important NOX isoforms related to SSc are NOX1, NOX2, and NOX4. Although the
highest expression levels of NOX1 are in colonic epithelium, this isoform is also abundantly
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expressed in endothelial cells and vascular smooth muscle cells. NOX2 is the classic
inflammatory isoform found in neutrophils and macrophages but is also expressed in Blymphocytes and in endothelial cells. NOX4 is highly expressed in the kidneys, however, it
displays very high expression in fibroblasts, smooth muscle cells, and endothelial cells as well as
in the lung.
ROLE OF NOX4 IN TISSUE FIBROSIS
Numerous recent studies have shown that NOX4 is a crucial molecule involved in the initiation,
establishment and development of tissue fibrosis. Indeed, multiple growth factors and related
polypeptides which participate in SSc pathogenesis [4-7] including TGF-ß, the most potent
cytokine implicated in the fibrotic process, as well as other profibrotic polypeptides including
PDGF, angiotensin II, and endothelin-1 have been shown to modulate the expression of NOX,
and in particular, that of NOX4. Stimulation of NOX4 expression by TGF-β has been
demonstrated in numerous recent studies [91-93]. PDGF, angiotensin II, and endothelin-1 have
also been shown to induce increased NOX4 expression [94-96]. NOX4 has been identified as a
source of ROS responsible for the generation and activation of TGF-β induced pulmonary,
cardiac and renal myofibroblasts in vitro [91-93, 97-102]. NOX4 is upregulated in lungs of
patients with IPF and in kidney and liver fibrosis [99,103,104]. NOX4-dependent generation of
ROS has been postulated to be involved in the fibrotic process in SSc [105,106], however,
experimental evidence in support of this hypothesis is still lacking. Of great relevance to the role
of NOX4 in the pathogenesis of the fibroproliferative vasculopathy in SSc is a recent study
demonstrating that ROS were capable of inducing the phenotypic conversion of endothelial cells
into activated myofibroblasts through a TGF-β dependent mechanism [107**].
Regulation of NOX4 activity.
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The mechanisms involved in the regulation of NOX activity are quite complex and it is likely
that they vary depending on a specific cellular and functional context. However, it is important to
emphasize that, in contrast with all other NOX enzymes, NOX4 does not require other protein
subunits for its activity and, therefore, the levels of its activity are dependent on the levels of
expression of its corresponding gene [108]. Given the important functions of NOX4 in a variety
of physiological processes and in the pathogenesis of numerous diseases, there has been intense
interest in unveiling the intimate mechanisms of its regulation. The mechanisms of increased
NOX4 expression by TGF-β are the focus of intense investigation [109,110]. A recent study
identified a far upstream AP-1/Smad binding element in the human NOX4 promoter that was
involved in the regulation of NOX4 expression by TGF-β [109].
Regarding the regulation of NOX4 activity one important mechanism has been recently
recognized. This study demonstrated a novel and quite important interaction of NOX4 with the
polymerase delta interacting protein 2 (PDIP2) that resulted in a three-fold stimulation of NOX4
activity by PDIP2 [111**]. The full significance of this important discovery is still not apparent
but undoubtedly represents a promising novel area for further investigation. Although the exact
mechanisms involved in the regulation of NOX4 levels in normal cells are becoming unveiled
the possible alterations responsible for the constitutive elevation in NOX4 levels and activity in
SSc cells have not been studied.
NOX4 inhibitors as a potential antifibrotic therapeutic intervention.
Following Murrell’s provocative hypothesis [60], numerous studies have provided strong
supporting evidence for a role of ROS in abnormal, exaggerated fibrogenesis, and for the
therapeutic targeting of ROS in fibrotic disorders such as SSc [112]. Indeed, a plethora of
clinical studies have examined a variety of pharmacological or naturally occurring antioxidant
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compounds as potential therapeutic agents for various aspects of the complex clinical
manifestations of SSc [113-122]. Most of the clinical studies examining the effects of antioxidant
therapy for SSc including some large placebo controlled clinical trials [122] have not provided
conclusive evidence of a therapeutical benefit. However, the recent demonstration of the crucial
role of NOX4 in the generation of ROS and the development of highly selective small molecule
inhibitors [123**,124**] and/or specific small synthetic peptide inhibitors targeting NOX4
[125**] offers substantial promise for the treatment of currently incurable fibrotic disorders,
such SSc or IPF [Reviewed in 126-128]. Indeed, numerous recent studies have shown that a
selective NOX1/NOX4 inhibitor exerted highly effective antifibrotic effect in various animal
models of tissue fibrosis [129-132]. The extensive study of Hecker et al. (131**) demonstrated
remarkable differences in the extent and severity of bleomycin-induced pulmonary fibrosis
induced in young mice compared to aged mice. These differences were caused by a NOX4induced senescence phenotype in fibroblasts from the aged animals that prevented fibrosis
resolution by rendering these cells resistant to apoptosis. The results demonstrated that persistent
lung fibrosis in aging was mediated by NOX4 induced oxidative stress that resulted in cellular
senescence and the acquisition of an apoptosis-resistant fibroblast phenotype. A remarkable
observation was the reversal of these phenotype following treatment with the NOX4 selective
small molecule inhibitor, GKT137831.
Although the extensive investigational studies reviewed above have suggested that specific or
selective NOX4 inhibitors may be of benefit for the therapy of SSc patients their beneficial
effects need to be conclusively demonstrated in rigorously controlled clinical trials.
CELLULAR SENESCENCE AND OXIDATIVE STRESS PATHWAYS LEADING TO
TISSUE FIBROSIS IN SSc.
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The causative agent or events and the exact mechanisms responsible for SSc development
remain unknown. However, extensive recent information about cellular senescence and oxidative
stress suggest a cogent hypothesis that may explain numerous observations obtained from the
study of SSc cells and tissues. This hypothesis postulates that the potent profibrogenic growth
factor, TGF-β becomes activated following its release from the TGF-β latent binding protein and
engages its cognate receptors in the surface of TGF-β-responsible cells. The sequence of events
resulting from active TGF-β receptor engagement leads to the upregulation of expression of
NOX4 mediated by the canonical Smad pathway although other non-canonical TGF-β signaling
pathways may be involved as well. Owing to the fact that NOX4 does not require additional cofactors and that its activity is largely determined by the levels of protein expression, the TGF-β
induced increase in NOX4 transcript levels results in increased NOX4-mediated ROS
production. Elevated ROS production would then initiate a cascade of events leading to the
establishment of an autocrine and paracrine self-stimulating pathway responsible for the
progressive fibrotic process in SSc. The main components of the autocrine/paracrine loop
induced by elevated ROS levels include the following:
1. Further release of TGF-β from the latent TGF-β complex.
2. Intracellular activation of TGF-β-dependent signaling pathways leading to the activation
of quiescent fibroblasts and the induction of the myofibroblast phenotype in these cells,
as well as in endothelial cells through the process of endothelial to mesenchymal
transition. The activated myofibroblasts are the cells ultimately responsible for the
fibrotic process in SSc. TGF-β also causes downregulation of genes encoding for
antifibrotic proteins such as cav-1 and PTEN or MMPs and other ECM degrading
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enzymes. Reduction of cav-1 and PTEN is also involved in stimulation of cellular
senescence as well as in stimulation of the pro-fibrotic phenotype.
3. ROS-mediated initiation and maintenance of cellular senescence. This is one of the
crucial components of the pathway initiated by ROS-mediated oxidative stress in the
target cells that results in tissue fibrosis. Although other mechanisms that cause cellular
senescence such as DDR or telomere shortening may also be involved, oxidative stress,
an important initiating event of cellular senescence is induced by elevated ROS levels.
4. The establishment of cell senescence in the target cells is accompanied by profound
structural and molecular changes including the expression of SASP and the secretion of
multiple proinflammatory and profibrotic molecules (Table 1).
5. The multiple components of the SASP exert potent effects on a variety of cells that are
involved in SSc pathogenesis including fibroblasts, endothelial cells and monocytes.
6. Cytokines and growth factors present in the SASP induce quiescent fibroblasts to become
activated and to acquire the profibrotic phenotype of activated myofibroblasts. These
cells produce exaggerated levels of various ECM macromolecular components and, also
display reduced expression and secretion of relevant metalloproteinases and other
proteases capable of degradation of ECM components.
7. The endothelial cells present in the microvasculature in proximity to the senescent cells
are also induced by SASP components to change their phenotype and become activated
myofibroblasts through endothelial to mesenchymal cellular transdifferentiation
processes.
8. Monocytes are attracted from the circulation through the effects of various cytokines and
chemokines present in the SASP and become activated. Following their activation
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macrophages are induced to change their phenotype into profibrotic M2 macrophages
which then establish a chronic inflammatory infiltrate in the affected tissues.
9. The activated M2 macrophages can directly contribute to the fibrotic process through the
production and secretion of profibrotic cytokines and growth factors causing further
stimulation of ECM production as well as, by enhancing the activation of quiescent
fibroblasts into myofibroblasts and by inducing the endothelial to mesenchymal transition
of endothelial cells.
10. The activated macrophages also contribute to the establishment of a vicious cycle
mediated by the macrophage production of TGF-β, and interferons and related
macromolecules. The macrophage production of TGF-β can induce further NOX4
production, and the interferon and related peptides can re-enforce the process of cellular
senescence, thus allowing the establishment of an autocrine and paracrine self-sustaining
mechanism that leads to tissue fibrosis.

CONCLUSION
There is strong experimental evidence supporting the concept that cellular senescence and ROSmediated oxidative stress play a crucial role in the initiation, establishment and the progression
of fibrosis in SSc and that these effects appear to involve NOX4. Therefore, the potential use of
specific NOX4 inhibitors for the treatment of SSc would be expected to be an effective
therapeutic approach. Although numerous clinical studies have examined the potentially
beneficial effects of various therapeutic interventions aimed at the reduction of oxidative stress
for SSc the results have not conclusively shown therapeutic effectiveness. Therefore, it will be
necessary to perform in vitro studies with specific or selective small molecule or peptide NOX4
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inhibitors followed by well designed placebo controlled clinical trials to document conclusively
any beneficial effects. Furthermore, clinical trials should also consider evaluating the use of
NOX4 inhibitors in combination with other drugs modulating different pathways of the complex
pathogenesis of SSc as this multidrug approach may result in improved therapy for this disabling
and frequently fatal disease.
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Legend to Figures.
Figure 1. Schematic diagram depicting the mechanisms involved in the induction of
SSc-associated tissue fibrosis by cellular senescence and ROS-mediated oxidative stress
and in the establishment of an autocrine/paracrine vicious cycle responsible for the
progression and persistence of the fibrotic process. 1. Release of TGF-β from the latent
TGF-β binding protein, followed by its activation and binding to cognate TGF-β
receptors. 2. Stimulation of transcription of the NOX4 gene leading to increased NOX4
and to increased ROS production. 3. Elevated ROS levels induce oxidative stress in the
target cells as well as phenotypic changes in fibroblasts and endothelial cells causing
their conversion into activated myofibroblasts. 4. Oxidative stress induces
morphological and functional changes of cellular senescence. 5. Senescent cells express
the senescence-associated secretory phenotype (SASP). 6-9.The components of the
SASP induce phenotypic changes in fibroblasts (6), endothelial cells (7) and monocytes
(8). The monocytes become activated M2 profibrotic macrophages that further increase
the fibrotic process (9). 10. The activated macrophages produce and secrete TGF-β and
interferons and various interferon-related molecules. The secreted TGF-β and
interferon related products close the vicious cycle and allow establishment of an
autocrine/paracrine pathway that is responsible for the initiation, and progression of
tissue fibrosis in SSc.
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